Sutro Biopharma

General Information
Business:

 

We are a clinical stage drug discovery, development and manufacturing company focused on leveraging our proprietary integrated cell-free protein synthesis platform, XpressCF, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders. We aim to design therapeutics using the most potent modalities, including cytokine-based immuno-oncology, or I/O therapeutics, antibody-drug conjugates, or ADCs, and bispecific antibodies that are directed primarily against clinically validated targets where the current standard of care is suboptimal.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 128
Founded: 2003
Contact Information
Address 310 Utah Avenue, Suite 150, South San Francisco, CA 94080, US
Phone Number (650) 392-8412
Web Address http://www.sutrobio.com
View Prospectus: Sutro Biopharma
Financial Information
Market Cap $332.3mil
Revenues $33.0 mil (last 12 months)
Net Income $-40.3 mil (last 12 months)
IPO Profile
Symbol STRO
Exchange NASDAQ
Shares (millions): 5.0
Price range $14.00 - $16.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Cowen/ Piper Jaffray
CO-Managers JMP Securities/ Wedbush PacGrow
Expected To Trade: 9/27/2018
Day: Thursday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change